ASCO 2025 | Enhancing our understanding of HRR gene defects in prostate cancer

Stefanie Zschaebitz • 2 Jun 2025

ASCO 2025

Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, emphasizes the need for a deeper understanding of homologous recombination repair (HRR) defects beyond BRCA1 and BRCA2 alterations in prostate cancer. PARP inhibitors can potentially benefit not only BRCA1 and BRCA2 mutated tumors but also those with other HRR mutations. Further research to elucidate the outcomes associated with specific HRR mutations and to explore combination approaches versus monotherapy to optimize treatment outcomes for patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think we should strengthen the knowledge about what is HRR in the community of practitioners, so that not only BRCA1 and BRCA2 altered tumors or patients with BRCA1 and BRCA2 altered tumors should receive PARP inhibitors, but I think also more research is needed to understand which HRR mutations have which outcomes, for example, and also which patients would benefit from a combination approach versus like a monotherapy...

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Disclosures

Honoraria – Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)
Consulting or Advisory Role – Amgen; Astellas Pharma (Inst); AstraZeneca; Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding – Eisai (Inst)
Travel, Accommodations, Expenses – Amgen; Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer